An emerging metabolic theory of pulmonary hypertension (PH) suggests that cellular and mitochondrial metabolic dysfunction underlies the pathology of this disease. We and others have previously demonstrated the existence of hyperproliferative, apoptosis-resistant, proinflammatory adventitial fibroblasts from human and bovine hypertensive pulmonary arterial walls (PHFibs) that exhibit constitutive reprogramming of glycolytic and mitochondrial metabolism, accompanied by an increased ratio of glucose catabolism through glycolysis versus the tricarboxylic acid cycle. However, the mechanisms responsible for these metabolic alterations in PH-Fibs remain unknown. We hypothesized that in PH-Fibs microRNA-124 (miR-124) regulates PTBP1 (polypyrimidine tract binding protein 1) expression to control alternative splicing of pyruvate kinase muscle (PKM) isoforms 1 and 2, resulting in an increased PKM2/PKM1 ratio, which promotes glycolysis and proliferation even in aerobic environments.
P
ulmonary hypertension (PH) is a prevalent comorbid condition that significantly worsens morbidity and mortality in patients with a wide variety of disorders. 1 In all these circumstances, PH is consistently associated with early and persistent perivascular inflammation, fibroproliferative changes, and pulmonary arterial remodeling. 2, 3 This remodeling involves an imbalance of cell proliferation versus cell death, which, taken in conjunction with inflammation, has led to the hypothesis that the cellular and molecular features of PH resemble hallmark characteristics of cancer. 4, 5 The fact that changes in cell metabolism in cancer cells and in cells in the surrounding stroma are essential for cancer cells to proliferate, migrate, and exhibit proinflammatory characteristics is now well recognized. Thus, there is an intense effort in the cancer field to define the mechanisms regulating the links among changes in metabolism, growth, and inflammation because they may offer new opportunities for therapy. It is striking that metabolic changes resembling those observed in cancer have also recently been reported in PH. 4, 6 These changes have been described to occur in smooth muscle cells, 6 endothelial cells, 7 and fibroblasts [8] [9] [10] and perhaps precede the development of PH. 11 These observations have led to a metabolic theory of PH whereby mitochondrial and cytosolic defects drive a Warburg-like cell phenotype (described originally for cancer cells, which reprogram metabolic pathways toward aerobic glycolysis to support high proliferation) that can explain the molecular and functional abnormalities seen in PH cells, including excessive proliferation, apoptosis resistance, and inflammation. 6, 8, 9, 12 Recently, however, it has become increasingly clear that there is a tremendous heterogeneity in how metabolic needs are met in different environmental/microenvironmental conditions. 13, 14 This dynamic character of the cellular metabolic network is commonly known as metabolic plasticity and is now recognized as an important feature of cell physiology. Thus, it is possible that the different cells that make up the pulmonary vascular wall might use distinct mechanisms to modulate metabolic and functional responses to environmental stress or injury.
Fibroblasts make up the principal cell population of the adventitia. In both the normal pulmonary and systemic vasculature, they are known to regulate vascular function through continuous production of extracellular matrix and matricellular proteins. 3, 15 Because of these functions, fibroblasts exhibit a distinct metabolic phenotype compared with many other nontransformed cells even when not dividing. 16 In addition, these cells are often the first to become activated, proliferate, and differentiate in response to injury. 3, 15 We have recently shown that pulmonary artery adventitial fibroblasts from calves with severe PH and humans with idiopathic pulmonary arterial hypertension (PHFibs) exhibit a distinct metabolic phenotype that is directly responsible for many aspects of their functional phenotype and could be a potential biochemical feature for cytotoxic drug selection. However, at present, little is known about the mechanisms that contribute to the generation and maintenance of the metabolic abnormalities observed in PH-Fibs. Deciphering the mechanisms that underlie this distinct metabolic reprogramming in PH-Fibs and other cells in the hypertensive vessel wall and identifying a novel, selective, and promising molecular target to alleviate PH is the overarching goal of our work.
In many rapidly proliferating cells and most cancer cells, pyruvate kinase (PK), the enzyme that produces pyruvate and ATP, has been implicated as a critical determinant of the metabolically altered cell phenotype. 17, 18 It is argued that pyruvate is at the center of
Clinical Perspective
What Is New?
• In pulmonary hypertension (PH), little is known about the mechanisms that contribute to the generation and maintenance of the metabolic abnormalities in pulmonary arterial cells, especially in fibroblasts.
• Here, we establish a clear link between microRNA-124 and its downstream target PTBP1 (polypyrimidine tract binding protein 1) to alterations in pyruvate kinase muscle (PKM) alternative splicing and thus alterations in the overall metabolic, proliferative, and inflammatory state of hypertensive adventitial fibroblasts.
• These findings support the novel hypothesis that pyruvate is at the center of the entire metabolic network, which confers metabolic flexibility of and between the cells in different microenvironmental conditions.
What Are the Clinical implications?
• We found in fibroblasts from the pulmonary hypertensive vessel that restoration of the PKM2/PKM1 ratio toward normal with microRNA-124 mimic and PTBP1 siRNA, pharmacological inhibition of PKM2 glycolytic function with TEPP-46 and shikonin, or treatment with histone deacetylase inhibitors reversed glycolytic and mitochondrial reprograming toward normal and decreased proliferative capacities.
• Inhibition of PKM2 glycolytic function in fibroblasts also abrogated their proinflammatory effects on macrophages.
• These findings provide additional mechanistic underpinnings for potentially targeting the microRNA-124-PTBP1-PKM axis as a novel therapeutic strategy in pulmonary hypertension.
the entire metabolic network. 14 Indeed, pyruvate occupies the junction between cytosolic and mitochondrial metabolism, and the pattern of pyruvate generation and disposition dictates in part the metabolic status of the cell. Pyruvate is synthesized by PK, which exists as either the M1 or M2 isoform or both in most cell types. PK muscle (PKM) is alternatively spliced to produce the PKM1 or PKM2 isoforms, which contain exon 9 or exon 10, respectively, and the regulation of the balance between these isoforms in cells is complex.
14,19 PKM1 and PKM2 are functionally different. PKM1 exists constitutively in a high-activity tetrameric form, whereas PKM2 exists in both a low-activity dimeric form and a high-activity tetrameric form. 20 The low-activity dimeric PKM2 is a very important driver for glycolysis by promoting conversion of pyruvate to lactate, the formation of which is promoted by tyrosine kinase-mediated phosphorylation that can be stimulated by environmental cues and growth factor signaling. On the other hand, high-activity PKM2 and PKM1 tetramers drive the tricarboxylic acid cycle. 17, 18 Recent studies suggest that heightened expression of PKM2 or an elevated PKM2/PKM1 ratio is critical for the maintenance of cancer cell growth. 17 Cells with an elevated PKM2/PKM1 ratio slow the production of pyruvate in response to proproliferative signaling, enabling utilization of glycolytic intermediates for the biosynthesis of cellular building blocks such as nucleotides, amino acids, and 1-carbon donors. 21 Neither the state of PKM isoform expression nor its function has been examined in PH fibroblasts or other pulmonary vascular cells to the best of our knowledge.
The state of PKM isoform expression is controlled by 3 hnRNPs (heterogeneous nuclear ribonucleoproteins), PTBP1 (polypyrimidine tract-binding protein 1; also known as hnRNPI), hnRNPA1, and hnRNPA2, that bind repressively to sequences flanking exon 9. In the presence of these PKM alternative splicing proteins, exon 10 is included in the mature PKM transcript, whereas exon 9 is excluded, resulting in a high PKM2/PKM1 ratio. 19, 22 Recent studies conducted in fibroblasts and different cell types, including ours, have implicated hnRNPs as downstream targets of miRNAs, including microRNA-124 (miR-124). [23] [24] [25] [26] We proved that miR-124 regulated PH-Fib proliferation through its direct target PTBP1. 24 A recent publication further showed that miR-124 inhibits cancer cell growth through a PTBP1/PKM1/PKM2 feedback cascade in colorectal cancer. 25 However, the function and relationships between miR-124, PTBP1, PKM1, and PKM2 in vascular cells have not been elucidated. We thus sought to test the hypothesis that in PH-Fibs high PTBP1 expression controlled by silenced miR-124 mechanistically underlies the elevated PKM2/PKM1 ratio, metabolic reprogramming, and heightened proliferative capacity in PH-Fibs.
METHODS
A detailed Methods section is provided in the online-only Data Supplement.
Animals
Neonatal calves and C57BL/6 mice exposed to chronic hypoxia were used in this study. All animal procedures were performed under the Guidelines for Animal Experimentation established and approved by the University of Colorado Anschutz Medical Campus and Colorado State University Institutional Review boards.
Cell Isolation and Culture
Bovine pulmonary artery adventitial fibroblasts were isolated from normal control calves or calves with severe experimental hypoxic PH as previously described 8, 24 ( Table I in the onlineonly Data Supplement). Human pulmonary artery fibroblasts were derived from patients with idiopathic pulmonary arterial hypertension or from control donors undergoing lobectomy or pneumonectomy as previously described 8, 9 ( Table II in the online-only Data Supplement). Cells were cultured under normoxic conditions. All experiments were performed on cells at passages 5 to 8.
Proliferation Assay
Cell proliferation was evaluated with the CyQUANT proliferation analysis Kit (Thermo Fisher Scientific, reference C7026).
Real-Time Reverse TranscriptasePolymerase Chain Reaction
Total RNA from fibroblasts was extracted and reverse-transcribed to cDNA as described previously. 24 All primer sets for real-time reverse transcriptase-polymerase chain reaction (RT-PCR) are listed in Table III in the online-only Data Supplement. Real-time RT-PCR product analysis was performed with iQ SYBR Green Supermix (Bio-Rad) in triplicate on the CFX96 Real-Time System (BioRad). Results were normalized to control groups with the δ-delta CT method.
Western Blot
Western blot was performed as previously described. 24 The specific antibodies for PTBP1 (Novus H00005725-M01), PKM1 (Novus NBP2-14833), PKM2 (Novus NBP1-48308), and β-actin (Sigma A5316) were used. Primary antibodies of phosphorylated pyruvate dehydrogenase (PDH), PDH, NDUFS4, and Tim23 were purchased from Abcam (Cambridge, MA). Signal was detected with enhanced chemiluminescence (Thermo Scientific). Quantitative analysis was performed by Image J software densitometry. Native gel electrophoresis assays were performed to evaluate the formation of tetrameric and dimeric PKM2.
Cell Transfection
Transfection was performed with 50 nmol/L of miR-124 mimic, scramble, or siRNA targeting PTBP1 or PKM2 (Table  III in the online-only Data Supplement) using DharmaFECT ORIGINAL RESEARCH ARTICLE Transfection Reagents as previously described. 24 The cells were harvested for mRNA expression after 48 hours of transfection and for protein expression after 72 hours of transfection. The cells were harvested for mass spectrometry-based ultrahigh-pressure liquid chromatography (UHPLC-MS) analysis and mitochondria metabolism analysis after 72 hours of transfection.
PTBP1 Plasmid Construction
The plasmids overexpressing PTBP1 from the cytomegalovirus promoter, which contained the full-length PTBP1 cDNA but not its authentic 3′ untranslated region that is resistant to miR-124-mediated inhibition, were constructed as previously described.
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PKM Splicing Reporter
The PKM splicing reporter was constructed by PCR-mediated amplification of the human PKM gene from exon 8 to 11, including introns from human genomic DNA, and inserted downstream of the cytomegalovirus promoter of the pcDNA3.1 vector (Invitrogen). The full-length PKM splicing reporter was sequenced.
Pharmacological Inhibition of PKM2 Glycolytic Function With TEPP-46 and Shikonin
The cultured cells were treated with a tetrameric PKM2 activator, TEPP-46 (30, 50, 75 ,100 µmol/L, EMD Millipore Corp, Billerica, MA) or the PKM2 glycolytic activity inhibitor shikonin (1.0 and/or 0.5 µmol/L, EMD Millipore Corp). The cells were harvested for protein expression after 72 hours of treatment. The cells were harvested for UHPLC-MS analysis and mitochondrial metabolism analysis after 72 hours of treatment. After 48 hours of treatment, condition medium was collected for experiments examining the effect of PH-Fibs on macrophages activation (see Methods in the online-only Data Supplement).
Histone Deacetylase Inhibitor Treatment
The cultured cells were treated with the pan-histone deacetylase (HDAC) inhibitor (HDACi) suberoylanilide hydroxamic acid (10 µmol/L, ChemieTek, Indianapolis, IN) or class I HDACi apicidin (3 µmol/L, Enzo, New York, NY) as previously described. 24 The cells were harvested for mRNA expression after 48 hours of treatment and for protein expression after 72 hours of treatment. The cells were harvested for UHPLC-MS analysis and mitochondrial metabolism analysis after 72 hours of treatment.
RNA Sequencing
As described previously, 8 RNAs from bovine CO-Fibs and PH-Fibs (n=6 each group) were used to perform RNA sequencing analysis.
MS-UHPLC Analyses
As described previously, 8 briefly, CO-Fibs and PH-Fibs 72 hours after transfection with siPKM2, miR-124 mimic, or siPTBP1 or after treatment with TEPP-46, shikonin, or HDACis (n=3, each group) were extracted (2×10 6 cells per 1 mL buffer) for metabolomics analyses through an UHPLC (Vanquish, Thermo Fisher).
Semiquantification of Matrix Superoxide Release Rate With Confocal Microscopy
MitoSOX Red (Life Technologies) was used to detect in situ surplus O 2 •− release to the matrix as described previously.
9
Semiquantification of Cytosolic Reactive Oxygen Species Levels With Confocal Microscopy and Spectrofluorometry
Carboxy-H2DCFDA (Life Technologies) was used for microscopic reactive oxygen species detection as described previously.
9
Semiquantification of Mitochondrial Membrane Potential With Confocal Microscopy
As described previously, 9 semiquantification of mitochondrial membrane potential was performed with the JC1 probe (Life Technologies).
High-Resolution Respirometry
As described previously, 9 O 2 consumption was measured with an Oxygraph 2k (Oroboros, Innsbruck, Austria).
Statistical Analysis
Values were expressed as mean±SEM. For basic comparisons of 2 gaussian-distributed sample sets, we used Student t tests, and for unequal variance sample sets, we used the Welch t test. GraphPad Prism software version 7.03 was used to perform 2-way repeated-measures ANOVA followed by the Sidak multiple-comparisons test and 1-way ANOVA with Tukey multiple column comparison test to compare means among a set of means resulting from different conditions. Differences with values of P<0.05 were considered statistically significant.
RESULTS
The Level of PKM2 Relative to PKM1 Is High in PH-Fibs, Accompanied by Decreased Mitochondrial Pyruvate Carrier and Sirtuin-3 Expression
To address the possible role of PKM in the distinct metabolic phenotype of PH-Fibs, 8, 9 PKM1 and PKM2 mRNA and protein levels in CO-Fibs and PH-Fibs were quantified. Compared with CO-Fibs, the hyperproliferative and proglycolytic bovine and human PH-Fibs exhibited significantly decreased levels of PKM1 mRNA ( Figure 1A and 1I) and protein ( Figure 1C Figure 1J and 1L) PH-Fibs was dramatically increased, which is primarily the result of the reduced PKM1 levels ( Figure 1A , 1C, 1I, and 1K). Consistent with in vitro data, immunofluorescent staining of PKM1 and PKM2 in CO and PH calf lungs demonstrates that PKM1 expression is very low (if not absent) in most cells of the remodeled adventitia, whereas PKM2 is expressed in almost all cells in the remodeled adventitia ( Figure IE in the online-only Data Supplement).
Cytosolic pyruvate synthesized by PK can be either transported into mitochondria or further processed to lactate under hypoxic conditions or, as in PH-Fibs, through aerobic glycolysis in cells expressing the glycolytic (Warburg) program. In previous studies, 8 we performed nuclear magnetic resonance and MS-based tracing experiments with heavy labeled substrates 13 C 1 -and U- 13 C-glucose to conclude that glucose catabolism through mitochondria is decreased in PH-Fibs, suggesting decreased shuttling of glycolytic pyruvate into mitochondria. Pyruvate is transported into mitochondria by the mitochondrial pyruvate carrier (MPC), which is composed of the MPC1 and MPC2 subunits, both of which exhibit decreased expression in cancer cells, with MPC1 being the most strongly and consistently affected. 27 Thus, we sought to investigate the expression of MPC as another indicator of pyruvate subcellular compartmentalization and utilization. We found decreased MPC1 expression in both bovine and human PH-Fibs ( Figure 1F and 1N ) and decreased MPC2 expression in human PH-Fib ( Figure 1O ). This result was confirmed by RNA sequencing in which the MPC1 transcript was reduced in bovine PH-Fibs ( Figure IF in the online-only Data Supplement). It is interesting to note that decreased activity of the mitochondrial deacetylase sirtuin-3 (SIRT3), which is known to modulate MPC expression, is associated with the development of PH. 28 Thus, we sought to determine whether the expression of SIRT3 would be altered in PH-Fibs. We found that SIRT3 mRNA expression is decreased in both bovine and human PH-Fibs ( Figure 1H and 1P). These observations are consistent with the decreased shuttling of glycolytic pyruvate into mitochondria in PH-Fibs.
Collectively, these findings, taken in the context of our previous report of increased PDH kinase-1 activity, 9 begin to explain the control of pyruvate and the metabolic phenotype of PH cells.
PKM2 Knockdown by siRNA Reverses the Metabolic and Proliferative Phenotypes of Human PH-Fibs
The increased PKM2/PKM1 ratios in PH-Fibs compared with CO-Fibs may be either correlative or causative with respect to the glycolytic metabolic reprogramming observed in PH-Fibs. 9, 29 To test the latter hypothesis and to directly address the role of altered PKM2/PKM1 ratio in the metabolic phenotype of PH-Fibs, we decreased the PKM2/PKM1 ratio by knocking down PKM2 using specific PKM2 siRNA in human PH-Fibs. As a result, PKM2 mRNA ( Figure 2A ) and the PKM2/PKM1 mRNA ratio (Figure 2B) were decreased dramatically in PH-Fibs treated with PKM2 siRNA, which was further supported by reduced PKM2 protein expression ( Figure 2C ). As expected, PKM1 protein levels were not decreased in PKM2 siRNAtreated cells, indicating the specificity of the PKM2 siRNA ( Figure 2C ). Steady-state UHPLC-MS demonstrated decreased lactate production ( Figure 2D ), and decreased levels of other metabolites involved in glycolysis and mitochondrial oxidative phosphorylation in human PH-Fibs after transfection with PKM2 siRNA, as gleaned with multivariate analyses (a detail of hierarchical clustering analysis), are shown in Figure 2E . Partial least-square discriminant analysis ( Figure 2F ) showed that siPKM2 altered the overall metabolic status of human PH-Fibs toward to COFibs. We also observed that the proliferation of PH-Fibs was significantly decreased by PKM2 knockdown with the CyQUANT assay ( Figure 2G ). To confirm the results, we evaluated the effects of PKM2 shRNA and verified significant decreases in proliferation ( Figure II in the onlineonly Data Supplement). Collectively, these results demonstrated an important role of the increased PKM2/PKM1 ratio in PH-Fibs in controlling the metabolic switch from glucose oxidation to aerobic glycolysis. Normalization of the PKM2/PKM1 ratio through PKM2 silencing abrogates metabolic dysfunction and decreases cell proliferation.
Pharmacological Inhibition of PKM2 Glycolytic Function by TTEP-46 and Shikonin in PH-Fibs Rescues Glycolytic Reprogramming and Decreases Cell Proliferation and Inflammatory Activation of Macrophages
Pharmacological intervention with the small-molecule TEPP-46 to promote PKM2 tetramer formation has been shown to reverse metabolic abnormalities and mitochondrial dysfunction, resulting in decreased cancer cell proliferation 30 and kidney pathology reversion. 31 Consistent with these observations, we found that TEPP-46 treatment of human PH-Fibs stabilized the PKM2 tetramer ( Figure IIIA in the online-only Data Supplement), with no effect on PKM1 expression ( Figure IIIB in the online-only Data Supplement). This resulted in decreased lactate generation in TEPP-46-treated PH-Fibs ( Figure 3A ) and a general correction of PH-Fibs metabolism. The levels of additional metabolites that accumulate in PH Fibs were normalized on TEPP-46 treatment, including glycolytic intermediates (glucose, glyceraldehyde 3-phosphate, fructose 1-6-bisphosphate, and lactate), metabolites associated with redox homeostasis (glutathione), mitochondrial function (α-ketoglutarate, succinate, and citrate), and pentose phosphate pathway (α-d-ribose 1-phosphate; Figure 3B ). The beneficial effect of TEPP-46 on PH-Fibs metabolism was paralleled by a decrease in cell proliferation ( Figure 3C ). We also observed that TEPP-46 rescued the mitochondrial bioenergetics by increasing ATP synthesis in bovine PH-Fibs, illustrated by the significantly increased respiratory control ratio ( Figure 3D ) and significant elevation of maximal respiratory capacity ( Figure 3E ). These results indicate that allosterically regulated PKM2 activity underlies metabolic reprogramming of PH-Fibs and that a tetrameric activator of PKM2 is sufficient to inhibit PKM2 glycolytic function and thus reverse the glycolytic and proliferative phenotypes of human PH-Fibs.
To further evaluate the role of PKM2 in controlling PH-Fib phenotype, we examined the effects of shikonin on PH-Fibs (bovine and human) on the basis of recent reports indicating that it is a potent PKM2 glycolytic function inhibitor in cancer cells and macrophages. 32 Metabolomics analyses revealed that treatment of PHFibs with shikonin was sufficient to normalize the metabolic phenotypes back to control values, as gleaned by multivariate analysis of bovine ( Figure IVA in the onlineonly Data Supplement) and human ( Figure 3H ) PH-Fibs. In human PH-Fibs, concentrations of both 0.5 and 1.0 µmol/L of shikonin were sufficient (1.0 µmol/L of shikonin resulted in more significant effects) to rescue the hyperglycolytic phenotype (as determined by higher steady-state levels of glucose and lactate compared with CO-Fibs; Figure 3F ). In bovine PH-Fibs, a concentration of 0.5 µmol/L of shikonin elicited a similar response ( Figure 4B in the online-only Data Supplement). Notably, shikonin treatment decreased additional glycolytic intermediates (d-fructose 1-6-bisphosphate, phosphoenolpyruvate, and glyceraldehyde 3-phosphate) and metabolites associated with redox homeostasis (cysteine and dehydroascorbate), mitochondrial function (succinate and fumarate), and pentose phosphate pathway (α-d-ribose 1-phosphate) in bovine ( Figure IVC in the online-only Data Supplement) and human (Figure 3G ) PH-Fibs. Consistent with this metabolic rescue, we observed that shikonin significantly reduced proliferation of bovine ( Figure IVD in the online-only Data Supplement) and human ( Figure 3I ) PH-Fibs.
We previously established that fibroblasts play an essential role in initiating and perpetuating the perivascular inflammation that characterizes PH. 8, 29, 33 They induce a distinct alternative macrophage phenotype that includes expression of mRNA for the proinflammatory cytokine interleukin (IL)-1β. 8, 29, 33 To further determine the role of PKM2 in fibroblast-mediated activation of macrophages, we exposed mouse bone marrow-derived macrophages to conditioned media from shikonin-treated PH-Fibs. We found that expression of IL-1β was significantly reduced in bone marrow-derived macrophages exposed to conditioned media from shikonin-treated PH-Fibs relative to dimethyl sulfoxide-treated PH-Fibs ( Figure in the online-only Data Supplement), which was previously shown to be PKM2 dependent. Having confirmed the direct role of excess PKM2 in the metabolic reprogramming of PH-Fibs, we sought to determine the molecular mechanisms underlying altered PKM2/PKM1 ratios in PH-Fibs. PTBP1, an alternative splicing factor, promotes generation of the PKM2 isoform by regulating PKM RNA splicing in tumor cells. 19, 22 We reported previously that PTBP1 is highly expressed in PH-Fibs and that PTBP1 is a direct target of miR-124, the expression of which is significantly reduced in PH-Fibs. 24 We observed that either overexpression of miR-124 or silencing of PTBP1 in bovine PH-Fibs reduced the PKM2/ PKM1 ratio ( Figure 4A and 4B) , indicating that miR-124 reduction or PTBP1 overexpression is critically important for the altered PKM2/PKM1 ratio observed in PH-Fibs. To determine whether miR-124 controls the PKM2/ PKM1 ratio by controlling PTBP1 levels, we cotransfected miR-124 mimics with a PTBP1 overexpression vector, pcDNA3.1-cytomegalorivus-PTBP1, which contained the full-length PTBP1 cDNA but not its authentic 3′ untranslated region that is resistant to miR-124-mediated inhibition. Transfection of miR-124-resistant pcDNA PTBP1 abrogated miR-124-mediated PKM2/PKM1 ratio reduction in bovine PH-Fibs ( Figure 4A and 4B) . These data supported the conclusion that miR-124 regulates PKM2/PKM1 ratio by controlling PTBP1 levels.
To further examine the role of PTBP1 in regulating PKM RNA splicing, we generated a human PKM splic- ing reporter that contains exon 8 to 11 of the human PKM gene ( Figure 4C ). PKM splicing reporter DNA was transfected into human CO-Fibs and PH-Fibs, and levels of total PKM (by vector-F/PKM total), PKM1 (by E9/E11/ vector-R), and PKM2 (by E10/E11/vector-R) transcripts produced from the splicing reporter were evaluated by quantitative RT-PCR. PKM2 transcripts were found to be highly expressed in PH-Fibs, much higher than that in the CO-Fibs ( Figure 4D ). Furthermore, PKM2 transcript levels were reduced by siPTBP1 or miR-124 mimic in PH-Fibs ( Figure 4D ). However, in contrast to the endogenous PKM gene, we were not able to detect PKM1 transcripts expressed from the splicing reporter. Nevertheless, the significant reduction of PKM2 by siPTBP1 is sufficient to support a role of PTBP1 in regulating the PKM alternative splicing process in fibroblasts.
To provide a possible explanation as to why PKM1 was dramatically decreased, although PKM2 did not increase significantly, we assessed the levels of the total PKM transcripts in CO and PH-Fibs. We observed that compared with CO-Fibs, total PKM expression was decreased in both bovine and human PH-Fibs ( Figure VIA and VIB in the online-only Data Supplement) by quantitative RT-PCR, a result that was confirmed by RNA sequencing in which PKM transcripts were reduced in bovine PH-Fibs by 1.69-fold ( Figure VIC in the online-only Data Supplement). It is interesting to note that despite the reduction of PKM gene transcription, the levels of PKM2 transcripts and proteins are still maintained or even slightly increased ( Figure I in the online-only Data Supplement), supporting our hypothesis that PKM2 splicing is favored in PH-Fibs.
It is possible that 2 other members of the hnRNP family of splicing factors, hnRNPA1 and hnRNPA2, also play a role in PKM alternative splicing in PH-Fibs because we found that hnRNA2 was increased in bovine PH-Fibs (Figure VIIB in the online-only Data Supplement) and both hnRNPA1 and hnRNPA2 were increased in human PH-Fibs ( Figure VIIF and VIIG in the online-only Data Supplement). Furthermore, we observed that knock- with Vector-R (located in vector sequence) was used for PKM1 or PKM2 transcripts expressed from the splicing reporter, whereas Vector F with PKM total was used to quantify the total transcripts produced from the splicing reporter. The total transcript results were used to control transfection/expression efficiency of the splicing reporter in control fibroblasts (CO-Fibs) and PH-Fibs. D, Relative PKM2 transcripts expressed from the splicing reporter in human CO-Fibs and PH-Fibs (with or without transfection of microRNA-124 mimic and siPTBP1). PKM2 levels were presented after calibration with total PKM transcripts expressed from the splicing reporter to control for transfection and expression variation between CO-Fibs and PH-Fibs (n=3). *P<0.05.
down of hnRNPA1 and hnRNPA2 decreased the PKM2/ PKM1 ratio in both bovine and human PH-Fibs ( Figure  VIIE and VIIJ in the online-only Data Supplement). These complementary findings merit further investigation.
miR-124 and PTBP1 Regulate the Relative Levels of PKM2 to PKM1 and Their Restoration Reverses the Glycolytic Switch in PH-Fibs
Having established altered expression and a functional role of increases in the PKM2/PKM1 ratio in PH-Fibs and the role of miR-124/PTBP1 in controlling PKM splicing axis, we wanted to determine whether miR-124 or PTBP1 regulates the PKM2/PKM1 ratio and thus the metabolic status in both bovine and human PH-Fibs. Using a well-established transfection system described previously, 24 we transiently transfected mature miR-124 mimic, PTBP1 siRNA, or scrambled siRNA sequence (as control) into the cells. Overexpression of miR-124 or silencing of PTBP1 in both bovine and human PH-Fibs caused a significant decrease in the PKM2/PKM1 mRNA ratio compared with PH-Fibs treated with scrambled siR-NA sequence, which was also corroborated by protein expression (Figure 5A and 5E). These data supported an important role of miR-124 and PTBP1 in regulating PKM2/PKM1 ratio in PH-Fibs.
To determine whether reduced miR-124 or increased PTBP1 expression is responsible for the metabolic phenotype observed in PH-Fibs, we performed extensive metabolic studies in pulmonary artery adventitial fibroblasts using UHPLC-MS. We found that miR-124 addback or PTBP1 reduction in PH-Fibs caused a significant decrease in lactate production compared with PH-Fibs treated with the corresponding scrambles ( Figure 5B and 5F). This is relevant in light of the hyperglycolytic phenotype of PH-Fibs 8 and the role of a Warburg-like phenotype in sustaining proliferation in a cancer-like fashion. 35 Multivariate analysis of MS metabolomics data revealed that miR-124 mimic and siPTBP1 altered the overall metabolic phenotypes of both bovine and human PH-Fibs toward CO (Principal component 1, which explains the highest percentage of the metabolic variance across samples, could discriminate PH-Fibs from the other groups for bovine and human cell experiments; Figure 5C and 5G). Heat maps generated from metabolomics analyses showed a reversion back to CO-Fibs levels of the metabolites involved in glycolysis and mitochondrial oxidative phosphorylation after transfection of PH-Fibs with miR-124 mimic or siPTBP1 (P<0.05, ANOVA; Figure 5D and 5H). Normalization of mitochondrial metabolism is relevant in light of the previously appreciated role of altered mitochondrial function in sustaining PH-Fibs proliferation, 9 a phenomenon accompanied by the accumulation of carboxylic acids to promote lipid anabolism and anaplerosis. 9, 35 In this view, particularly intriguing was the restoration of serine, glutamine, succinate, α-ketoglutarate, and ribose phosphate to normal after treatment with miR-124 mimic or siPTBP1 ( Figure VIII in the onlineonly Data Supplement). Although only steady-state measurements were performed, these results suggest a role of miR-124 in controlling glutaminolysis/glutathione homeostasis, pentose phosphate pathway, and 1-carbon metabolism, key regulatory pathways for the biosynthesis of nucleosides, and thus contributing to the hyperproliferative phenotype of PH-Fibs. 8, 35 Taken together, these data demonstrated the functional role of miR-124 and PTBP1 on the PKM2/PKM1 ratio axis, which in turn controls the metabolic switch from glucose oxidation to aerobic glycolysis in PH-Fibs.
Normalization of miR-124 or PTBP1 Levels Reverses Mitochondrial Abnormalities in PH-Fibs
Increased glycolysis is reported to provide the cell with sufficient building blocks for cell proliferation. Although most tumor cells have functional mitochondria, their activity is altered. 36 Our recent work suggests that mitochondrial abnormalities may play a central role in PH-Fibs activation. 9 Thus, after having established the role of miR-124 and PTBP1 on aerobic glycolysis in PHFibs, we sought to identify the effects of miR-124 and PTBP1 on mitochondrial activity. To determine whether altered miR-124 and PTBP1 expression is responsible for constitutive reprogramming of mitochondrial metabolism in PH-Fibs, we evaluated respiratory parameters of bovine fibroblasts, focusing on intensity and capacity of oxidative phosphorylation, along with the activity of respiratory chain complexes with emphasis on complex I.
Using a variety of redox-sensitive probes, we determined redox status in both the mitochondria and cytosol in bovine PH-Fibs in response to changes in the level of miR-124 or PTBP1 within the cell. We found a significantly decreased phosphorylated PDH/total PDH ratio in PH-Fibs transfected with miR-124 mimic or siPT-BP1 ( Figure 6A ), which facilitates pyruvate oxidation in the mitochondria of cells. We found that either miR-124 add-back or silencing PTBP1 rescued the mitochondrial bioenergetics by increasing ATP synthesis in PH-Fibs, illustrated by increased respiratory control ratio and elevation of maximal respiratory capacity ( Figure 6B and  6C) . Furthermore, we observed rescue of mitochondrial complex I activity ( Figure 6D ), which was accompanied by increased expression of the NDUFS4 assembly subunit of complex I ( Figure 6E ) after either overexpression of miR-124 or silencing of PTBP1. Increased mitochondrial bioenergetics in PH-Fibs with miR-124 overexpression or PTBP1 silencing led to a decrease of mitochondrial mem-brane potential ( Figure 6F ), corresponding to a drop in mitochondrial superoxide production ( Figure 6G ) and cytosolic reactive oxygen species ( Figure 6H) . Together, these studies demonstrated that restoration of miR-124 or reduction of PTBP1 is sufficient to rescue mitochondrial reprogramming in PH-Fibs.
HDACis Normalize the PKM2/PKM1 Ratio and Reverse the Metabolic Reprogramming of PH-Fibs
Reversible lysine acetylation has emerged as a critical mechanism for controlling the function of nucleosomal histones and diverse nonhistone proteins. Roles for HDACs as therapeutic targets in PH have been increasingly recognized. 37, 38 We have previously shown that PH-Fibs have increased class I HDAC expression 29 and that HDACis restore miR-124 expression and decrease PTBP1 expression. 24 Thus, we were interested in determining whether HDACis would also reverse the metabolic phenotype of PH-Fibs. We observed that incubation of PH-Fibs with the pan-HDACi suberoylanilide hydroxamic acid or with the selective class I HDACi apicidin reduced the PKM2/PKM1 ratio ( Figure 7A and 7D), decreased glucose uptake and lactate production ( Figure 7B and 7E) , and decreased levels of metabo- lites involved in glycolysis and mitochondrial oxidative phosphorylation ( Figure 7C and 7F) . These findings provide additional mechanistic underpinnings for targeting HDACs as a novel therapeutic strategy in PH.
To investigate the effects of HDACi treatment on mitochondrial function, we performed extensive mitochondrial function studies in bovine PH-Fibs. We observed that HDACi treatment (suberoylanilide hydroxamic acid and apicidin) significantly increased the respiratory control ratio ( Figure 8A ), maximal respiratory capacity ( Figure 8B ), complex I activity ( Figure 8C) , and NDUFS4 subunit of complex I expression ( Figure 8D ) in bovine PH-Fibs. We also found mitochondrial superoxide production (Figure 8E ) and cytosolic reactive oxygen species production ( Figure 8F ) decreased after HDACi treatment, which is consistent with recent work by Chen et al.
37
Shikonin Treatment Attenuates the Metabolic, Proliferative, and Inflammatory Changes in Lungs of Hypoxic Mice
Because of the striking effects of PKM2 inhibition on PH-Fibs metabolism, proliferation, and macrophage in- A, Quantification of phosphorylation of pyruvate dehydrogenase (PDH) expressed as phosphorylated PDH (P-PDH)/total PDH protein ratio in PH-Fibs transfected with miR-124 mimic or siPTBP1 (top). Representative Western blots for phosphorylated PDH and total PDH in PH-Fibs are shown (bottom). Respiratory control ratio expressed as endogenous (state 3)/ATP synthase-inhibited (oligomycin, state 4) respiratory ratio (B), maximal respiratory capacity expressed as uncoupled (FCCP)/ ATP synthase-inhibited (oligomycin, state 4) respiratory ratio (C), and in situ quantification of complex I activity determined by rotenone-inhibited decrease of respiration (100% represents nontreated samples; D) in control fibroblasts (CO-Fibs) treated with scrambled siRNA (SCR) and PH-Fibs targeted with SCR, miR-124 mimics or siPTBP1 are shown. E, Quantification of NDUFS4 subunit of complex I in PH-Fibs after transfection by Western blot analysis using specific NDUFS4 antibodies (top). Representative Western blot is shown (bottom), including control of protein loading (Tim23 quantification). Mitochondrial membrane potential expressed by JC1 ratio (F), mitochondrial superoxide expressed by MitoSOX fluorescence increase rate (Jm; G), and cytosolic reactive oxygen species production detected with the 2',7'-dichlorofluorescein (DCF) probe (H) were revealed in CO-Fibs and PH-Fibs after transfection with miR-124 mimic or siPTBP1 (n=3-4). *P<0.05 vs SCR-treated PH-Fibs.
teractions, we performed preliminary experiments examining the effects of shikonin in hypoxic mice ( Figure  IXA in the online-only Data Supplement). Despite the limited number of biological replicates, we found, using principal component analysis of metabolomics, that shikonin treatment at a dose of 8.0 mg/kg rescued (at least partially) the metabolic alterations observed in the hypoxic lung ( Figure IXB in the online-only Data Supplement). In particular, significant improvements were observed with respect to lung amino acid levels, nitrogen metabolism, and glycolysis ( Figure IXC in the onlineonly Data Supplement). We also examined the effect of shikonin on cell proliferation, inflammatory cell recruitment, and provisional extracellular matrix accumulation using lungs immunofluorescently stained for Ki67, CD68, and tenascin C, respectively. We observed significant reductions in proliferation and proinflammation phenotypes in shikonin-treated lung ( Figure IXE in the online-only Data Supplement). We observed a nonsignificant trend in right ventricular systolic pressure with shikonin treatment ( Figure IXD in the online-only Data Supplement) in hypoxic mice. From these preliminary results, further extensive evaluation of the effects of manipulating PKM2 in various models of PH and vascular remodeling is indicated.
DISCUSSION
An emerging metabolic theory of PH suggests that common metabolic and mitochondria-based cell dysfunction may underlie the disease pathology.
4,39 Thus, numerous molecular abnormalities described in pulmonary vascular cells may have a common denominator, that is, mitochondrial suppression of glucose oxidation with upregulation of cytoplasmic glycolysis, similar to cancer cells. We showed previously that PH-Fibs exhibit profound metabolic changes 8, 9, 24, 29 that may begin to explain functional abnormalities, including hyperproliferation, apoptosis resistance, and a proinflammatory state. These observations emphasize that the metabolic reprogramming of PH-Fibs (or other vascular wall cells) presents a potential therapeutic strategy. We now show that similar to cancer cells, high PTBP1 expression, controlled by decreased expression of miR-124, mechanistically underlies the elevated PKM2/PKM1 ratio and subsequent metabolic reprograming in PH-Fibs. In an accompanying article, we demonstrate that a very simi- HDACi treatment significantly increased respiratory control ratio (A), maximal respiratory capacity (B), complex I activity (C), and NDUFS4 subunit of complex I (D) in bovine PH-Fibs. Mitochondrial superoxide production (Jm; E) and cytosolic reactive oxygen species (ROS) production (F) decreased after HDACi treatment (n=3-4). *P<0.05 vs dimethyl sulfoxide (DMSO)-treated PH-Fibs. G, Proposed mechanism contributing to metabolic reprogramming in PH-Fibs. In PH-Fibs, the state of pyruvate kinase muscle (PKM) isoform expression is controlled by an alternative splicing complex, composed of PTBP1 (polypyrimidine tract binding protein 1), hnRNP (heterogeneous nuclear ribonucleoprotein) A1, and hnRNPA2. In the presence of these PKM alternative splicing proteins, especially PTBP1 (a direct target of microRNA-124 [miRNA-124]), exon 10 is included in the mature PKM transcript, whereas exon 9 is excluded, resulting in a high PKM2/PKM1 ratio. The elevated PKM2/PKM1 ratio is critical for the constitutive reprogramming of glycolytic and mitochondrial metabolism, accompanied by an increased ratio of glucose catabolism through glycolysis vs the tricarboxylic acid (TCA) cycle and increased ROS levels. PH-Fibs with an elevated PKM2/PKM1 ratio slow the production of pyruvate in response to proproliferative signaling, enabling utilization of glycolytic intermediates for biosynthesis of cellular building blocks, which promote cell proliferation. Restoration of the PKM2/PKM1 ratio toward normal with miR-124 mimic and siPTBP1, pharmacological inhibition of PKM2 glycolytic function with TEPP-46 and shikonin, or treatment with HDACi reverses glycolytic and mitochondrial reprograming toward normal. These findings provide additional mechanistic underpinnings for potentially targeting the miR-124-PTBP1-PKM axis as a novel therapeutic strategy in PH. SAHA indicates suberoylanilide hydroxamic acid. lar miR-124-PTBP1-PKM signaling axis also controls the metabolic and functional state of pulmonary artery endothelial cells and blood outgrowth endothelial cells in human idiopathic pulmonary arterial hypertension and familial pulmonary arterial hypertension. 40 The present study also demonstrates a distinct PKM profile of pulmonary artery adventitial fibroblasts, which is different from that observed in many cancer cells. Most cancer cells assessed in cell culture preferentially express PKM2 over PKM1, and PKM2 is important for cancer metabolism and tumor growth. 17, 19 It is interesting to note that in PH-Fibs, PKM1 expression is dramatically decreased, but PKM2 is not remarkably increased. In other words, decreased PKM1 is the main contributor to the increased PKM2/PKM1 ratio and the low PK activity in PH-Fibs and not elevated PKM2 per se. These results support the idea that the absolute elevations in PKM2 are not required for cell metabolic reprogramming. Rather, the low PK activity, resulting primarily from low PKM1 expression, is the major contributor to the PH-Fibs metabolic switch. Furthermore, as we show in this study, in PH-Fibs, overexpression of miR-124, knockdown of PTBP1, and HDACi treatment all restore expression of PKM1, normalize the PKM2/PKM1 ratio, and restore the metabolic phenotype toward control cells ( Figure 8G ). These results, including upregulation of hnRNPA1/A2 in human PH-Fibs, are consistent with observations in certain cancer cells where downregulation of the splicing factors hnRNPA1/A2 and PTBP1 rescued PKM1 expression and decreased aerobic glycolysis. 19 Collectively, these findings provide additional mechanistic underpinnings for potentially targeting the miR-124-PTBP1-PKM axis as a novel therapeutic strategy in PH.
Our findings of what appears to be a dynamic and flexible metabolic network controlled principally at the level of pyruvate metabolism through changes in the PK isoform expression are compatible with the emerging principle of metabolic plasticity in cells throughout the body. Recent studies support the idea that, to a greater or lesser extent, most cells carry out metabolism in very distinct ways.
14 Intriguing observations from Lemons et al 16 suggest that fibroblasts exhibit a distinct metabolic phenotype under conditions of both quiescence and proliferation. Even under quiescent conditions, fibroblasts exhibit a high metabolic activity compared with other cells, which is thought to be the result in part of their role in the synthesis, breakdown, and resynthesis of proteins and lipids and the secretion of extracellular matrix proteins. Because they are often the first to become activated in response to vascular injury, it is clear that fibroblasts must have a capability of rapidly adapting to their microenvironment and, as we know, may accomplish this by rapidly altering their metabolic network in response to environmental needs. Numerous studies support the idea that the selection for absolute or relative increases of PKM2 in proliferating cells promotes a unique metabolic program through reduced PK enzymatic activity. In particular, low PK enzymatic activity, as would occur when PKM2 is preponderant, has been proposed to divert glycolytic intermediates toward biosynthetic pathways such as the pentose phosphate pathway and serine biosynthesis. 13, 41 Consistent with studies in cancer, our current and previous tracing experiments in PH-Fibs clearly indicated increased anabolic fluxes for nucleoside synthesis, serine biosynthesis, and pentose phosphate pathway activation. 8 Here, small-molecule regulation of PKM2 by stabilization of its tetrameric form with TEPP-46, pharmacological inhibition of PKM2 glycolytic activity with shikonin, or restoration of the PKM2/PKM1 ratio toward normal in PH-Fibs with miR-124 mimic, siPTBP1, and especially by HDACi led to decreased levels of ribose phosphate and serine, intermediates required for the biosynthesis of nucleotides and proteins, or the generation of reducing equivalents necessary to fuel lipid synthesis and to keep in check the redox poise (eg, NADPH). 13 It is also important to note that PKM2 enzymatic activity can be inhibited through endogenous mechanisms, which supports the idea that selection for PKM2 in certain highly synthetic or proliferating cells can confer metabolic flexibility by allowing PK enzymatic activity to be turned on or off in response to the environment. Expression of PKM1, on the other hand, likely renders cells less responsive to intracellular cues on energy state, nutrient availability, and growth.
Our observations suggest that different from the metabolic inflexibility observed in certain cancer cells, these hypertensive fibroblasts are still able to change rapidly, especially in response to environment or pharmacological interventions. Our findings support the idea that pyruvate metabolism can be exquisitely controlled by miR-124 and PTBP1. It is known that in oxidative cells, pyruvate is transported into the mitochondria by MPC. Decreased expression and activity of MPC seem to be an essential feature of the metabolic program in many cancer cells. Our observations of decreased MPC1 expression in PH-Fibs are consistent with these observations. It is interesting to note that our observations of decreased SIRT3 expression are also compatible with the reports demonstrating that decreased activity of SIRT3, which is known to modulate MPC activity, is associated with the development of PH. 28 Relevant also are observations that SIRT3 is downregulated in constitutively activated fibroblasts from patients with systemic sclerosis and that its pharmacological activation mitigates fibrosis. 42 It is known that SIRT3 responds directly to mitochondrial NAD + levels. Thus, it is likely that the increased NADH/ NAD + ratio in bovine and human PH-Fibs, together with intensive glycolysis, represses SIRT3 activity. The next step in the carbohydrate oxidation pathway is the conversion of pyruvate to acetyl Co-A in the mito-chondrial matrix by PDH. We recently showed that in PH-Fibs, PDH is markedly inhibited by the activation of PDH kinase-1.
9 Our data clearly demonstrate that restoration of miR-124 or reduction of PTBP1 toward normal restored PDH activity and led to the restoration of mitochondrial respiratory capacity and complex I activity and reductions in mitochondrial membrane potential, superoxide production, and cytosolic reactive oxygen species production. These results strongly support the idea that miR-124 and PTBP1 play an important role in mitochondrial abnormalities in PH-Fibs, likely through control of pyruvate metabolism. Further studies of these metabolic mitochondrial alterations in PH may therefore provide new therapeutic perspectives in this disease.
MiR-124 may have targets other than PTBP1 that are important in controlling the metabolic, proliferative, and proinflammatory phenotype of PH-Fibs. It has been shown that hnRNPA2, as a component of PKM splicing complex, is also an miR-124 target gene. 23 This may explain that in our experiments restoration of miR-124 with miR-124 mimic resulted in more significant effects on the metabolic profile than siPTBP1 ( Figure 5 ). It has also been shown that miR-124 selectively targets both human and mouse monocarboxylate transporter lactate/pyruvate transporter 3′ untranslated regions, thus potentially regulating the ability of the tumor cells to secrete lactate. 43 Monocarboxylate transporter 1 is part of a core Wnt signaling gene program for glycolysis in colon cancer. Monocarboxylate transporter 1 can export lactate, the byproduct of Warburg metabolism, and it is the essential transporter of pyruvate and a glycolysis-targeting cancer drug, 3-bromopyruvate. 44 Consistent with this, we have observed that PH-Fibs activate naive macrophage by secreting IL-6 33 and lactate (unpublished). Results shown here indicated that inhibiting PKM2 in fibroblasts and macrophages can abrogate this proinflammatory fibroblast-macrophage interaction. Thus, considering the prominent role of miR-124 in lactate production in fibroblasts in the present study, miR-124 may underlie the cell-cell interaction between fibroblasts and macrophages, thus meriting further investigation to seek glycolysis-targeting drugs for PH.
We investigated the possibility that HDACis could reverse the metabolic abnormalities observed in PH-Fibs on the basis of the previous observations, including ours, that class I HDAC (1,2,3) activity is increased in PH-Fibs 38 and that HDACis decrease proliferation in PH-Fibs, 38 increase miR-124 expression, 24 and prevent and reverse hypoxia-induced PH. 37, 38, 45 The present work aimed at determining the mechanisms involved in these responses shows that HDACis (suberoylanilide hydroxamic acid and apicidin) can normalize the PKM2/PKM1 ratio, shift the metabolic state toward oxidative phosphorylation, and rescue mitochondria abnormalities in PH-Fibs. Because we previously established that the catalytic activity of class I HDACs is increased in PH-Fibs and that HDACis can restore miR-124 expression and decrease PTBP1 expression, 29 it is possible that the mechanism of HDACi on reversing the metabolic abnormalities of PH-Fibs is at least partly through the miR-124/PTBP1/PKM axis. Our results are consistent with those in several cancers, where it has been shown that genetic knockdown of individual HDACs, most notably HDAC1, 2, 3, and 6, in a variety of tumor types induced apoptosis and cell cycle arrest, implicating HDAC activity as a key mediator of survival. 46 Indeed HDACis can induce tumor cell apoptosis, growth arrest, senescence, differentiation, and immunogenicity and inhibit angiogenesis at least in certain cancer cell types. Collectively, these findings suggest that it would be nearly impossible to conceive of a single mechanism of action that would be responsible for these effects of HDACis in different cell types. In cancer, it is accepted that therapeutic outcomes will likely depend on the genetic lesions driving the tumor of interest and the HDACis under investigation. Our studies demonstrate that PH-Fibs are a cell in which HDAC inhibition can significantly abrogate the miR-124-PTBP1-PKM2 axis, thereby having or resulting in significant effects on metabolism and cell function.
Conversely, it has also been shown that metabolic intermediates may control HDAC activity in cancer cells. 47 This may represent a cross-talk connecting cell metabolism, transcription, and other HDAC-controlled processes in physiological and pathological conditions. This provides direction for future research because it will be important to evaluate the potential existence of a positive feedback for PH in which metabolism and HDACs cross-talk to drive vascular remodeling.
The treatment of PH has historically been restricted by a limited number of therapeutic options. Endothelial dysfunction and abnormal proliferation and contraction of smooth muscle cells represent logical pharmacological targets. 48, 49 Despite recent major improvements in symptomatic treatments, no current treatment cures this devastating condition. 50 Recent advances in our understanding of the pathophysiological and molecular mechanisms, the new paradigm of an "outside-in" hypothesis in which the adventitial compartment is viewed as a critical regulator of vessel wall function, 51 and the emergence of adventitial fibroblasts with constitutive proinflammatory, glycolytic, and mitochondrial reprogramming phenotypes may orchestrate recruitment, retention, and activation of circulating inflammatory cells. 8, 9, 29 Perhaps inside-out and outside-in hypothesis are not mutually exclusive. The work by Caruso et al shows that very similar signaling pathways exist in resident endothelial cells and endothelial progenitors. These authors also show a link between the most common genetic causes of pulmonary arterial hypertension, mutations in the bone morphogenetic protein type II receptor, and the miR-124/PTBP1/ PKM axis. Thus, common metabolic abnormalities may underlie pulmonary arterial hypertension and may lead to the development of new pharmacological therapies, providing renewed hope for both patients and their physicians. Studies presented here using genetic, epigenetic, and small-molecule approaches to reverse metabolic reprogramming and proliferative status in adventitia fibroblasts may offer new therapeutic opportunities in this disease.
